November 18, 2022 11:26 AM EST

FDA hits Iovance with one more delay for TIL therapy, extending BLA filing until 2023

Amber Tong

Iovance Biotherapeutics is once again pushing back its filing plans for its cell therapy — the latest in a three-year streak of delays — although execs say …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA hits Iovance with one more delay for TIL therapy, extending BLA filing until 2023

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

FDA hits Io­vance with one more de­lay for TIL ther­a­py, ex­tend­ing BLA fil­ing un­til 2023

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

FDA hits Iovance with one more delay for TIL therapy, extending BLA filing until 2023

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial